scholarly journals Concurrent Invasive Ductal Carcinoma of the Breast and Malignant Follicular Lymphoma, Initially Suspected to Be Metastatic Breast Cancer: A Case Report

2014 ◽  
Vol 17 (1) ◽  
pp. 91 ◽  
Author(s):  
Myong Hun Hahm ◽  
Hye Jung Kim ◽  
Kyung Min Shin ◽  
Seung Hyun Cho ◽  
Ji Young Park ◽  
...  
2017 ◽  
Vol 10 (1) ◽  
pp. 27-36 ◽  
Author(s):  
Dong-hyun Lee ◽  
Sung-su Kim ◽  
Shin Seong

The purpose of this case report is to show the potential benefit of Korean medicine therapy for treating multiple metastatic breast cancer. A 45-year-old Korean woman was diagnosed with right breast invasive ductal carcinoma in August 2012 but did not receive any treatment until October 2015 when she was diagnosed with stage 4 right breast cancer with multiple liver, bone, mesentery, retroperitoneum, and axillary lymph node metastases. After chemo-port insertion, she was treated with palliative chemotherapy and the first line of trastuzumab and paclitaxel, and the port was removed due to port infection. To treat sepsis, vancomycin and tazoperan were administered, before the third line of trastuzumab and paclitaxel was carried out. However, the patient gave up chemotherapy due to vancomycin-resistant enterococci and general weakness. Later, she received Korean medicine therapy with wild ginseng pharmacopuncture, distilled Soramdan S, Hae, and Jeobgoldan for 8 months, which led to a significant decrease of the multiple metastases. The patient was able to start walking again with the help of a walking stick. However, a new metastatic lesion was found on the right adrenal gland. This case suggests that the combination of chemotherapy and Korean medicine therapy may be valuable. Further research is indicated.


2014 ◽  
Vol 7 (4) ◽  
pp. 1001-1006 ◽  
Author(s):  
MIKAKO TAMAOKI ◽  
YOSHINORI NIO ◽  
KAZUHIKO TSUBOI ◽  
MARIKA NIO ◽  
MASASHI TAMAOKI ◽  
...  

2011 ◽  
Vol 236 (2) ◽  
pp. 145-155 ◽  
Author(s):  
Geetika Chakravarty ◽  
Krzysztof Moroz ◽  
Nick M Makridakis ◽  
Shelby Alaine Lloyd ◽  
Sarah E Galvez ◽  
...  

2011 ◽  
Vol 17 (5) ◽  
pp. 521-524 ◽  
Author(s):  
Soley Bayraktar ◽  
Monica T. Garcia-Buitrago ◽  
Erin Hurley ◽  
Stefan Gluck

2020 ◽  
Vol 13 (1) ◽  
pp. 304-308 ◽  
Author(s):  
Alyssa Schlotman ◽  
Adam Stater ◽  
Kyle Schuler ◽  
Judd Heideman ◽  
Vandana Abramson

A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib. Fulvestrant was determined to be the drug most likely responsible for this hepatotoxic effect. This case report details the timing and nature of this drug-induced liver injury, adding support to an area that has yet to be described adequately in the existing literature.


2020 ◽  
Vol 13 (2) ◽  
pp. 544-549
Author(s):  
Giacomina Megaro ◽  
Luigi Rossi ◽  
Serena Ceddia ◽  
Marsela Sinjari ◽  
Adele Mannino ◽  
...  

In the case of our patient, the synergic action of endocrine therapy and chemotherapy plus dual anti-HER2 combination allowed a complete disease control. Therapy should be scheduled by considering the two cancers as individual entities. The approach to breast cancer is changing from being considered a singular disease to a multiform one, according to current research focused on biological markers such as HER2, ERs, and PRs, with important implications in clinical, prognostic, and therapeutic features.


Sign in / Sign up

Export Citation Format

Share Document